Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception
Full Year 2021 Preliminary Unaudited Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020
Company Reiterates All Previously Provided Financial Targets
Ongoing Strategic Review & Debt Refinancing Activities
https://finance.yahoo.com/news/adma-biologics-announces-record-preliminary-120000914.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.